Foundry Partners, LLC Biomarin Pharmaceutical Inc Transaction History

Foundry Partners, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 01, 2024	BUY	$76.22 - $98.51 $171,876 - $222,140	2,255 New	2,255 $217,000
Q1 2023 May 03, 2023	SELL	$87.74 - $117.27 $4,299 - $5,746	-49 Reduced 1.51%	3,188 $310,000
Q4 2022 Jan 30, 2023	BUY	$80.93 - $108.63 $161 - $217	2 Added 0.06%	3,237 $335,000
Q3 2022 Oct 21, 2022	BUY	$82.16 - $96.94 $265,787 - $313,600	3,235 New	3,235 $274,000
Q1 2022 Apr 14, 2022	SELL	$74.28 - $92.69 $178,346 - $222,548	-2,401 Closed	0 $0
Q4 2021 Jan 26, 2022	BUY	$71.72 - $91.47 $172,199 - $219,619	2,401 New	2,401 $212,000
Q3 2021 Oct 14, 2021	SELL	$74.77 - $85.47 $179,522 - $205,213	-2,401 Closed	0 $0
Q2 2021 Jul 23, 2021	BUY	$75.51 - $84.79 $181,299 - $203,580	2,401 New	2,401 $200,000
Q1 2021 May 12, 2021	SELL	$74.73 - $90.69 $179,426 - $217,746	-2,401 Closed	0 $0
Q4 2020 Feb 04, 2021	BUY	$72.61 - $90.2 $174,336 - $216,570	2,401 New	2,401 $211,000
Q3 2020 Oct 23, 2020	SELL	$71.87 - $131.03 $172,559 - $314,603	-2,401 Closed	0 $0
Q2 2020 Aug 03, 2020	BUY	$79.55 - $124.22 $190,999 - $298,252	2,401 New	2,401 $296,000

632

185M

1.63M

1.2M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Foundry Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Foundry Partners, LLC with notifications on news.